Takeda and Metabolon Initiate Research Collaboration
News Apr 18, 2012

Metabolon, Inc. has announced that Metabolon and Takeda Pharmaceutical Company Limited have formed a multiyear research alliance that will focus on discovering therapeutic targets and biomarkers.
Metabolon has developed a proprietary analytical platform and software for biomarker discovery using metabolomics to accelerate drug discovery and development by accurately measuring the spectrum of biochemical changes in biological samples, and mapping these changes to their corresponding metabolic pathways.
Metabolon will apply its platform to discover and validate targets, and identify novel pharmacodynamic biomarkers for translation into the clinic.
Metabolon’s CEO John Ryals said, “We are excited about the prospect of collaborating with Takeda to accelerate its research programs. Metabolon has built a unique platform and has accumulated a vast amount of institutional knowledge in the field of metabolome analysis. We believe that integrating metabolomic profiling into Takeda’s R&D programs may lead to novel therapies and more informed decisions.
RELATED ARTICLES
Like what you just read? You can find similar content on the communities below.
Biopharma Drug Discovery Proteomics & MetabolomicsTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019
26th Annual Cardiologists conference
Jul 10 - Jul 11, 2019